Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PDE8B | O95263 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046911 | 1.00 | KDM1A (0.44) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL1050048 | 1.00 | KDM1A (0.44) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL20410 | 0.96 | SMN1; SMN2 (0.45) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL863388 | 0.96 | SMN1; SMN2 (0.45) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL1779025 | 0.96 | SMN1; SMN2 (0.45) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL23951039 | 0.91 | PDE8B (0.46) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL24876030 | 0.91 | PDE8B (0.46) | KDM1APDE8BSMN1; SMN2ATMEPHX1 | |
| SCHEMBL29039374 | 0.90 | SMN1; SMN2 (0.39) | SMN1; SMN2ATMEPHX1HSD17B10HPGD | |
| SCHEMBL11995197 | 0.90 | SMN1; SMN2 (0.39) | SMN1; SMN2ATMEPHX1HSD17B10HPGD | |
| SCHEMBL13220199 | 0.87 | PDE8B (0.43) | KDM1APDE8BSMN1; SMN2ATMEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375423-B2 | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis | ASANA BIOSCIENCES, LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| EP-1725530-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-6150352-A | ARYLQUINOLONE ANALOGS | MERCK & CO., INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6147088-A | USEFUL FOR THE TREATMENT OF A VARIETY OF SEX-HORMONE RELATED CONDITIONS | MERCK & CO., INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0901471-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0901471-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0901489-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997044339-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997044321-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | KDM1A 2847/4885PDE8B 478/4885SMN1; SMN2 4444/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | KDM1A 1849/4885PDE8B 4174/4885SMN1; SMN2 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.